INTRODUCTION {#sec1-1}
============

Breast cancers (BCs) are the most frequent malignancy among women that can be a leading cause of death through middle-aged women. Despite the fact that BC is a major health issue, very few studies describe its characteristics in the Middle East.\[[@ref1]\] BCs can be divided based on their gene expression profiles, into at least four groups: Luminal-type, the human epidermal growth factor receptor 2 (HER2)-type, normal-like-type, and basal-type. Luminal-type cancers are characterized by an activated estrogen receptor (ER) signaling pathway and are divided into two subtypes, luminal subtypes "A" and "B". In general, luminal-subtype-A tumors express higher levels of ER and carry a better prognosis than do luminal-subtype-B tumors.\[[@ref2]\] ER positivity predicts response to endocrine therapy such as antiestrogen (tamoxifen) and trastuzumab therapy (herceptin) for tumor with HER2 overexpression.\[[@ref3]\] Ki-67 is a nuclear antigen, which exists in proliferative cells. A number of studies have shown that the immune response of Ki-67 is closely associated with the cell cycle. Furthermore, Ki-67 may predict the pathological remission rate in BC patients following neoadjuvant chemotherapy, as an increased Ki-67 level following neoadjuvant chemotherapy indicates a poor prognosis.\[[@ref4]\] A meta-analysis involving 12, 155 patients demonstrated that the Ki-67 positivity confers a higher risk of recurrence and a worse survival rate in patients with early BC. Even though this meta-analysis could not scrutinize if Ki-67 had independent prognostic value beyond the standard clinicopathological variables, it confirmed that the high levels of Ki-67 are associated with worse prognoses.\[[@ref5]\] The other important biological markers in early BC are tumor size, nuclear grade, axillary lymph node involvement, ER, progesterone receptor (PR), and HER2 status. Uncontrolled proliferation (such as Ki-67) is a key characteristic of malignant tumors and, therefore, tumor proliferation is one of the major factors associated with prognosis.\[[@ref6][@ref7]\]

The aim of this study was to evaluate the use and value of Ki-67 as a prognostic marker in BC and associations between Ki-67, clinical, and histopathological parameters were evaluated.

SUBJECTS AND METHODS {#sec1-2}
====================

Patients {#sec2-1}
--------

In a retrospective study, 260 BC women and invasive ductal carcinoma were included to our study in Kermanshah City, Iran. They received chemotherapy, radiotherapy, or hormone therapy. A lot of patients underwent primary surgery. A sufficient sample size was selected from any patient, and the slides were stained by hematoxylin and eosin (H and E) method. Then 4 µ sections were prepared for staining with H and E and also for immunohistochemical (IHC) (Ki-67, ER, PR, p53, and HER2) staining. ER and PR positivity was defined as ≥10% positive tumor cells with nuclear staining. The HER2 positive was defined as either HER2 gene amplification by fluorescent *in situ* hybridization (FISH) or scored as 3+ by IHC. In case of HER2 (2+), FISH was performed to determine HER2 positivity. The age, tumor size, lymph node involvement, histological grade, nuclear grade, and vascular invasion were other factors that determined in a lot of patients.

In this study, hormone receptor (HR)-positive and HER2-negative tumors were classified as luminal A type; HR-positive and HER2-positive tumors (HER2 IHC: 3+ or 2+ that amplifiedbyFISH) as luminal B type; HR-negative and HER2-positive tumors as HER2 disease; and HR-negative and HER2-negative tumors as triple negative (TN) type.\[[@ref8]\]

Statistical analysis {#sec2-2}
--------------------

Statistical analyses were performed using the IBM SPSS version 19 (SPSS Inc., Chicago, IL, USA). Chi-square test was used to analyze the significance of correlation between the expression of Ki-67 and other parameters. The value *P* \< 0.05 was considered significant.

RESULTS {#sec1-3}
=======

The mean age at diagnosis was 47.6 years (range, 24-84 years) with 100% female. Of 243 patients that tumor size was determined for them, 207 patients (85.2%) had tumor size ≥2 cm, and 36 patients (14.8%) had size \<2 cm and also of 237 patients, 47 patients (19.8%), 140 (59.1%), and 50 (21.1%) had histological Grades I, II, and III, respectively \[[Table 1](#T1){ref-type="table"}\]. We had nuclear grade for 152 patients that 35 patients (23%), 90 (59.2%), and 27 (17.8%) were Grades I, II, and III, respectively. Of 242 patients, 155 patients (64%) had lymph node involvement and of 206 patients, 135 patients (65.5%) had vascular invasion. Of all patients, 156 (60%), 149 (57.3%), and 106 (40.8%) were ER^−^, PR^−^, and HER2^−^ positive, respectively. Of 231 patients, P53-positve was in 104 patients (45%). We divided Ki-67 to two groups: 144 patients (55.4%) had low Ki-67 (Ki-67 \<20%) and 116 patients (44.6%) with high Ki-67 (Ki-67 ≥20%).

###### 

The baseline characteristics of patients with breast cancer (*n* = 260)

![](IJMPO-37-95-g001)

The correlation between Ki-67 with other factors in BC patients has been shown in [Table 2](#T2){ref-type="table"}. There is a significant correlation between Ki-67 with nuclear grade, HER2, and p53 (*P* \< 0.05). Based on this result, more patients with Ki-67 ≥20% have a higher nuclear grade, p53-positive, and HER2-positive.

###### 

The correlation between Ki67 with other factors in breast cancer patients
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The [Figure 1](#F1){ref-type="fig"} shows the number of patients based on Ki-67 for types of tumor. There was correlation between Ki-67 with type of tumor (*P* = 0.009). Therefore, more TN patients have high Ki-67 and more patients with other subtypes have low Ki-67.

![Number of patients based on Ki67 and types of tumor](IJMPO-37-95-g003){#F1}

DISCUSSION {#sec1-4}
==========

Invasive breast carcinoma is the most common malignant tumor in women worldwide and is a heterogeneous disease with distinct pathological and histological features and can be classified into several subtypes based on the expression of 3 receptors: ER, PR, and HER2.\[[@ref3]\] Ki-67 is an immunohistochemical proliferation marker in many types of cancer and has been widely studied among BC patients mostly through retrospective studies.\[[@ref9]\]

In our study, higher Ki-67 expression was more frequently associated with HER2-positive. A number of other studies also showed that a higher Ki-67 index significantly correlated with HER2-positive,\[[@ref6][@ref8][@ref10][@ref11]\] but in other study, HER2-negative had significantly higher Ki-67 values.\[[@ref12]\]

A higher nuclear grade\[[@ref8][@ref12][@ref13][@ref14]\] had a direct significantly correlation with higher Ki-67 and also the overexpression of p53 bears a direct statistically significant relationship to Ki-67.\[[@ref8][@ref15][@ref16]\] In TN patients has been shown that there is a direct correlation between Ki-67 and p53 that more patients with p53-positive had high Ki-67.\[[@ref15]\] In our study, higher Ki-67 expression was more frequently associated with higher nuclear grade and p53-positive.

A number of studies reported that a higher Ki-67 index significantly correlated with larger tumors,\[[@ref8][@ref10][@ref17]\] positive lymph nodes.\[[@ref8][@ref18]\] Therefore, Ki-67 expression in axillary lymph nodes is significantly higher in lymph nodes than that in primary cancer in some cases.\[[@ref19][@ref20]\] A total of 194 cases of diagnosed BC were included in a study that significant association was found between Ki-67 and tumor grade, PR, and lymph node status, but no link was apparent with ER positivity and tumor size.\[[@ref11]\] A number of studies reported that among classical histopathological parameters, grading was strongly correlated to Ki-67-labeling indices.\[[@ref10][@ref21][@ref22]\] Other studies showed that ER status has been largely identified as being inversely correlated with Ki-67, with the higher rates of ER positivity shown in the lowest proliferating tumors.\[[@ref8][@ref9][@ref12][@ref21]\] In our study, there is a significant correlation between tumor size, lymph node involvement, histological grade, ER, and PR status with Ki-67.

A study reported that in univariate analyses, high Ki-67-labeling index was associated with vascular invasion.\[[@ref10]\] Furthermore, in other studies had been shown that vascular and lymphatic invasion associated with higher Ki-67 values.\[[@ref10][@ref23]\]

A higher Ki-67 index significantly correlated with younger age.\[[@ref8]\] In a study reported that in BC, there is a strong correlation has been found between the percentage of cells positive for Ki-67 and age.\[[@ref13][@ref14]\] In our study, there was no significant correlation between Ki-67 with age and vascular invasion. Possible cause of the difference in the results of various studies returns to type of division for Ki-67. In a number of studies, Ki-67 has been divided based on ≥10% and \<10% and other studies based on ≥20% and \<20% such as our study, and even a few studies based on other numbers. For a good result about correlation between Ki-67 with other factors in BC, it needs that the researchers do the studies based on a constant and accurate number.

The results in a study with 960 patients with BC showed that in luminal A patients, only one had a Ki-67 level higher than 20%. In luminal B, the Ki-67 was higher than 20% in 51.16% of the patients. In the HER2 subtype, the Ki-67 level was more than 20% in 48.63%. In TN patients, Ki-67 was more than 20% in 63.86%. The data indicated that the level of Ki-67 may be considered one of the valuable biomarkers in BC patients.\[[@ref24]\] In our study, the Ki-67 ≥20% was 45.9%, 39%, 20.8%, and 58.2% in luminal A, luminal B, HER2 disease, and TN patients, respectively. Therefore, TN patients have more Ki-67 ≥20% (high Ki-67) compared to other subtypes.

CONCLUSIONS {#sec1-5}
===========

The higher Ki-67 has a direct significant correlation with higher nuclear grade; p53-positive and HER2-positive. Furthermore, TN patients have higher Ki-67 compared to other subtypes. For a good result about correlation between Ki-67 with other factors in BC, it needs that Ki-67 indexing divided based on a constant and accurate percent in the future studies.
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